Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy
Study Details
Study Description
Brief Summary
Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Background: Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking.
Methods: Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit. Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). 193 patients with AGC from January 2010 to December 2018 in two different China university hospitals were included in this study. The before neoadjuvant chemotherapy imaging scoring system (BNCISS), imaging change scoring system before and after neoadjuvant chemotherapy (ICSS), which were constructed based on computed tomography images before after treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| good response to neoadjuvant chemotherapy (GRNC) Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC) |
Other: response to neoadjuvant chemotherapy
Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
|
| poor response to neoadjuvant chemotherapy (PRNC) TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). |
Other: response to neoadjuvant chemotherapy
Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
|
Outcome Measures
Primary Outcome Measures
- AUC for ICSS [2022-01-01 to 2022-07-31]
The predictive performance of imaging change scoring system before and after neoadjuvant chemotherapy (ICSS)
- AUC for BNCISS [2022-01-01 to 2022-07-31]
The predictive performance of before neoadjuvant chemotherapy imaging scoring system (BNCISS)
Secondary Outcome Measures
- overall survival [2010-01-01 to 2022-07-31]
3 year overall survival
- disease free survival [2010-01-01 to 2022-07-31]
3 year disease free survival
Eligibility Criteria
Criteria
Inclusion Criteria:
- Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection
Exclusion Criteria:
- Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Gastric Surgery | Fuzhou | Fujian | China |
Sponsors and Collaborators
- Fujian Medical University
Investigators
- Study Director: Hualong Zheng, 291167038@qq.com
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FMUUH-001